Trial: 202111094

A Phase 3, Single Arm, Open Label Study of Evaluating Ovarian Suppression Following Three Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Breast Cancer

Phase

III

Principal Investigator

Peterson, Lindsay

Disease Site

Breast

Learn more about this study at: clinicaltrials.gov